Press Release
Terumo Appoints the Candidates for Directors
TOKYO, JAPAN – May 14, 2024 – Terumo Corporation (TSE: 4543) hereby announcesthat it has decided the candidates for directors as below. The elections are subject tothe approval of the Annual General Meeting of Shareholders to be held on June 26,2024.
1. Candidates for directors(Excluding directors who serve as Audit and Supervisory CommitteeMembers)Name

New position

Toshiaki Takagi

Chairman of the Board

Same as on the left

Representative Director and Chief Executive

Hikaru Samejima

Current position

Officer

Chief Executive OfficerDirector and Group Senior Managing Executive

Group Senior ManagingOfficer

Executive Officer

Kazunori Hirose

Director and Group Managing Executive Officer

Same as on the left

Norimasa Kunimoto

Director and Group Managing Executive Officer

Same as on the left

Hidenori Nishi

Independent Director

Same as on the left

Keiya Ozawa

Independent Director

Same as on the left

Mari Kogiso

Independent Director(New candidate)Toshihiko Osada

2. New Candidate for directors
Hikaru Samejima: Chief Executive Officer

Name

HikaruSamejima(Born onMay 27,

Professional Career
April 1988

Joined Toa Nenryo Kogyo Corporation (now ENEOS Corporation)

February 2001

Joined Citi Bank N.A.

January 2002

Joined the Company

June 2007

President, Terumo Interventional Systems (Global), Cardiac and
Vascular Group

April 2014

Executive Officer
Division President, Interventional Systems Division, Cardiac and1964)

Vascular Company
April 2016

Senior Executive Officer

April 2017

President, Cardiac and Vascular Company

April 2018

Managing Executive Officer

April 2020

President, General Hospital Company (now Medical Care Solutions
Company)

April 2022

Group Senior Managing Executive Officer

April 2024

Chief Executive Officer (current)

Toshihiko Osada: Group Senior Managing Executive Officer
NameProfessional Career
April 1989Joined the Company

January 2016

General Manager, Strategic Planning Department

April 2016

Executive Officer

April 2018

Senior Executive Officer

April 2020

Managing Executive Officer

ToshihikoPresident, Cardiac and Vascular Company

OsadaDivision President, Interventional Systems Division, Cardiac and(Born on

Vascular Company

January 28,

April 2022

Group Senior Managing Executive Officer (current)

1967)

April 2024

In charge of Innovation;
R&D Division (CTO Office, Innovation Center, Technology
Coordination Office, R&D Administration Department),
DX Promotion Department, Intellectual Property Department,
Clinical Development Department, Terumo Medical Pranex(current)

Mari Kogiso: Founder and CEO, SDG Impact Japan Inc.
Name

Professional Career
April 1990

Joined Long-Term Credit Bank of Japan, Limited

June 1998

Joined World Bank

June 2003

Representative, Asia, Multilateral Investment Guarantee Agency,
World Bank Group

Mari Kogiso(Born onNovember 15,1966)

October 2012

Founder and CEO, I Incubate Corporation

October 2014

Representative, Dalberg Japan

January 2016

Head of International Business Planning, Sasakawa Peace
Foundation

July 2017

General Manager, Gender Investment and Innovation Division,
Sasakawa Peace Foundation

June 2019

General Manager, CEO Office, FAST RETAILING CO., LTD.

January 2021

Founder and CEO, SDG Impact Japan Inc. (current)

June 2022

Independent Audit & Supervisory Board Members, Mitsubishi

Corporation (current)

3. Director to resign from the Board
Shinjiro Sato
Shoji Hatano
Yukiko Kuroda

About Terumo
Terumo (TSE:4543) is a global leader in medical technology and has been committed
to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo andoperating globally, Terumo employs more than 30,000 associates worldwide toprovide innovative medical solutions in more than 160 countries and regions. Thecompany started as a Japanese thermometer manufacturer, and has beensupporting healthcare ever since. Now, its extensive business portfolio ranges fromvascular intervention and cardio-surgical solutions, blood transfusion and celltherapy technology, to medical products essential for daily clinical practice. Terumo
will further strive to be of value to patients, medical professionals, and society atlarge.